Investors & Media

Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.

Latest News

Dr. Selwyn Ho appointed new CEO of Medigene


Medigene provides Q1 2022 update


Medigene publication details augmentation of PRAME-specific TCR-4 by PD1-41BB switch receptor


The Medigene Share

The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. 

show medigene share


03 Aug 2022

6-Months Report 2022

07 - 08 Sep 2022

Stifel London Cross Sector Insight Conference

19 - 21 Sep 2022

Berenberg and Goldman Sachs 11th German Corporate Conference

02 Nov 2022

Quarterly Statement Q3 2022

Corporate Governance

Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.

read more

press photos

Laboratory work

DownLoad (9 MB)

Laboratory work (6)

Cell culture work

DownLoad (4 MB)

Laboratory work (7)

Cell sorting

DownLoad (353 KB)

Contact person

Dr. Anna Niedl
Vice President Investor Relations & Corporate Communications
Phone: +49 89 2000 3333 01
Fax: +49 89 2000 33 2920